Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: magrolimab, evorpacept | 0.81 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 10 Parkinson's papers of 3,683 | 0.69 |
| pathways Reactome | 4 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 10319
Sealed predictions
- CD47 in dopamine neurons, braak-0.16 (p 0.685) → +0.54 (p 0.137)receipt 10327
Swarm cases
receipt 10327: CD47 in dopamine neurons, braak
- power
- full sample +0.18 (p 0.465, n 18), 95% CI -0.31 to +0.60. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.15 (p 0.561, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.14 (p 0.567, n 18). could be the mix.
- skeptic
- leave-one-out range +0.08 to +0.32, sign flips 0; without severely affected donors +0.18 (p 0.465, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for CD47 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts